Xiangxue Life Sciences Shines at 2025BIOCHINA South China with Breakthrough TCR-T Therapies

(Source: Xiangxue Pharmaceutical)

Source: Xiangxue Pharmaceutical

Based in Guangzhou, Linking the Greater Bay Area

2025BIOCHINA South ChinaGrandly opened on October 10, 2025, at the Xianglan Guanzhou Hotel on Guangzhou Bio Island!

This conference invites 3400+ participants, with leading enterprises gathering, bringing together 170+ cutting-edge research experts and perceptive investors to discuss the critical path from technological breakthroughs to industrial implementation. The event features 13 major thematic forums and 70+ content-sharing sessions, covering antibody drugs & XDC, cell therapy, nucleic acid drugs, gene therapy, peptide drugs, small molecule drugs, exosome drugs, and more.

Xiangxue Pharmaceutical/Xiangxue Life SciencesAs a leading company in China's TCR-T tumor immunotherapy field, Xingyao attended this conference. Several individuals, including Mr. Wang Yonghui, Chairman of Xiangxue Pharmaceutical, were invited to participate in the forum and delivered excellent keynote speeches.

Chairman Wang Yonghui Participates in Roundtable Discussion "Bay Area Innovation Equation: Pipeline Breakthroughs, Ecosystem Co-construction, and Global Collaboration"

Chairman Wang Yonghui stated that in today's era, Chinese pharmaceutical companies must rely on biomedicine to go global. The Guangdong-Hong Kong-Macao Greater Bay Area, whether in terms of geographical location or policy-driven advantages, is fertile ground for the growth of biomedical enterprises. Relying on the internationalization advantages of Hong Kong and Macao, it is easier to achieve the overseas expansion of locally innovative biopharmaceuticals. We should seize the opportunity to achieve more breakthroughs.

Xiangxue Life SciencesCSO Mr. Zhong Shi Participates in Roundtable Discussion "Breakthroughs in Cell Therapy for Autoimmune and Solid Tumor Indications"

Xiangxue Life SciencesAssistant to the General Manager & Senior Scientist Mr. Zhan Kai delivers a keynote report: Application of High-Affinity TCR-T Products in the Field of Solid Tumor Treatment

Xiangxue Life SciencesMr. Qu Yusheng, Production Director, Delivers Keynote Report: Research on Pharmaceutical Changes During Clinical Trials of Cell Therapy Products

At this conference, Xiangxue Life Sciences was rated as "2025 Innovative Breakthrough Enterprise", Mr. Wang Yonghui, Chairman of the Board, represented the company in receiving the award on stage.

As a leader in China's TCR-T tumor immunotherapy, Xiangxue Life Sciences garnered significant attention at this conference, being the focus of interest before, during, and after the event. The audience showed strong interest in Xiangxue Life Sciences' TCR-T products, with an enthusiastic response.

The attending guests all expressed that the focus on the biopharmaceutical industry is deepening, with substantial progress achieved in various fields. Capital is showing initial signs of recovery, and investment logic has become more mature, providing confidence to R&D-driven enterprises. The industrial advantages of the Greater Bay Area offer unique opportunities for innovative companies, and we, as innovative biopharmaceutical enterprises, must seize these opportunities to lead the way!

About Xiangxue Life Sciences

GuangDong XIANGXUE LIFE SCIENCES LTD ("Xiangxue Life Sciences"), a holding subsidiary of Xiangxue Pharmaceutical, is a leading company in China specializing in the research and development of cell immunotherapy products and technologies in the TCR field. The company envisions "addressing the challenges of human health and setting a benchmark for cancer treatment" and is on a mission to "focus on TCR, empower T cells, and conquer solid tumors."

GuangDong XIANGXUE LIFE SCIENCES LTD owns the proprietary intellectual property rights to the core TCR technology and has a complete TCR-T cell therapy product research and development platform and production system. The TCR-T cell therapy product R&D platform includes: ① Antigen Peptide Discovery Platform, ② TCR Affinity Optimization Platform, ③ Full-process TCR-T Development Platform; the TCR-T cell therapy product production system includes: ① Automated Cell Production Platform, ② Quality Control Platform. It has formed a full-chain innovation for TCR-T cell products.New IndustryChain.

Xiangxue Life Sciences' TCR-T products and pipeline reserves are extensively laid out, with a rich array of targets including CT antigens, neoantigens, and viral antigens, covering almost all tumor-related specific antigens. They encompass multiple HLA genotypes predominant in the Chinese population, such as A0201, A1101, and A2402, with indications covering various clinically challenging solid tumors, placing them at an internationally leading level.

Currently, Xiangxue Life Sciences has two products that have obtained IND approval in China. The first product is TAEST16001, indicated for soft tissue sarcoma (later expanded to esophageal cancer and non-small cell lung cancer). It has completed Phase I clinical trials and the first phase of Phase II clinical trials in China. It has been included in the list of breakthrough therapies and has entered the confirmatory clinical trial stage, with the potential to become the first TCR-T cell therapy product in China and the second globally. The second product is TAEST1901, indicated for primary liver cancer and other solid tumors, which is initiating Phase I clinical trials. Another candidate product, XLS-103, indicated for advanced pancreatic cancer, non-small cell lung cancer, and colorectal cancer, is currently undergoing IND application.

Source: Xiangxue Life Sciences